268 related articles for article (PubMed ID: 8856831)
41. Delta(9)-THC-induced cognitive deficits in mice are reversed by the GABA(A) antagonist bicuculline.
Varvel SA; Anum E; Niyuhire F; Wise LE; Lichtman AH
Psychopharmacology (Berl); 2005 Mar; 178(2-3):317-27. PubMed ID: 15322725
[TBL] [Abstract][Full Text] [Related]
42. Anxiety does not affect the antinociceptive effect of Delta 9-THC in mice: participation of cannabinoid and opioid receptors.
Takahashi RN; Ramos GA; Assini FL
Pharmacol Biochem Behav; 2003 Jul; 75(4):763-8. PubMed ID: 12957217
[TBL] [Abstract][Full Text] [Related]
43. Precipitated cannabinoid withdrawal is reversed by Delta(9)-tetrahydrocannabinol or clonidine.
Lichtman AH; Fisher J; Martin BR
Pharmacol Biochem Behav; 2001; 69(1-2):181-8. PubMed ID: 11420084
[TBL] [Abstract][Full Text] [Related]
44. Central and peripheral mechanisms contribute to the antiemetic actions of delta-9-tetrahydrocannabinol against 5-hydroxytryptophan-induced emesis.
Darmani NA; Johnson JC
Eur J Pharmacol; 2004 Mar; 488(1-3):201-12. PubMed ID: 15044052
[TBL] [Abstract][Full Text] [Related]
45. Opioid and cannabinoid modulation of precipitated withdrawal in delta(9)-tetrahydrocannabinol and morphine-dependent mice.
Lichtman AH; Sheikh SM; Loh HH; Martin BR
J Pharmacol Exp Ther; 2001 Sep; 298(3):1007-14. PubMed ID: 11504797
[TBL] [Abstract][Full Text] [Related]
46. In vivo characterization of a specific cannabinoid receptor antagonist (SR141716A): inhibition of delta 9-tetrahydrocannabinol-induced responses and apparent agonist activity.
Compton DR; Aceto MD; Lowe J; Martin BR
J Pharmacol Exp Ther; 1996 May; 277(2):586-94. PubMed ID: 8627535
[TBL] [Abstract][Full Text] [Related]
47. Involvement of opioid system in cognitive deficits induced by ∆⁹-tetrahydrocannabinol in rats.
Egashira N; Manome N; Mishima K; Iwasaki K; Oishi R; Fujiwara M
Psychopharmacology (Berl); 2012 Feb; 219(4):1111-8. PubMed ID: 21858449
[TBL] [Abstract][Full Text] [Related]
48. Reversal of delta 9-THC hyperphagia by SR141716 and naloxone but not dexfenfluramine.
Williams CM; Kirkham TC
Pharmacol Biochem Behav; 2002; 71(1-2):333-40. PubMed ID: 11812541
[TBL] [Abstract][Full Text] [Related]
49. Physical withdrawal in rats tolerant to delta 9-tetrahydrocannabinol precipitated by a cannabinoid receptor antagonist.
Tsou K; Patrick SL; Walker JM
Eur J Pharmacol; 1995 Jul; 280(3):R13-5. PubMed ID: 8566091
[TBL] [Abstract][Full Text] [Related]
50. Cannabinoid ligands and their effects on learning and performance in rhesus monkeys.
Winsauer PJ; Lambert P; Moerschbaecher JM
Behav Pharmacol; 1999 Sep; 10(5):497-511. PubMed ID: 10780256
[TBL] [Abstract][Full Text] [Related]
51. Biphasic effects of Δ9-tetrahydrocannabinol on brain stimulation reward and motor activity.
Katsidoni V; Kastellakis A; Panagis G
Int J Neuropsychopharmacol; 2013 Nov; 16(10):2273-84. PubMed ID: 23830148
[TBL] [Abstract][Full Text] [Related]
52. Antagonism of discriminative stimulus effects of delta(9)-THC and (R)-methanandamide in rats.
Järbe TU; Liu Q; Makriyannis A
Psychopharmacology (Berl); 2006 Jan; 184(1):36-45. PubMed ID: 16307294
[TBL] [Abstract][Full Text] [Related]
53. Relative involvement of cannabinoid CB(1) and CB(2) receptors in the Delta(9)-tetrahydrocannabinol-induced inhibition of natural killer activity.
Massi P; Fuzio D; Viganò D; Sacerdote P; Parolaro D
Eur J Pharmacol; 2000 Jan; 387(3):343-7. PubMed ID: 10650181
[TBL] [Abstract][Full Text] [Related]
54. Decrease in efficacy and potency of nonsteroidal anti-inflammatory drugs by chronic delta(9)-tetrahydrocannabinol administration.
Anikwue R; Huffman JW; Martin ZL; Welch SP
J Pharmacol Exp Ther; 2002 Oct; 303(1):340-6. PubMed ID: 12235269
[TBL] [Abstract][Full Text] [Related]
55. Spatial signal detection in rats is differentially disrupted by delta-9-tetrahydrocannabinol, scopolamine, and MK-801.
Presburger G; Robinson JK
Behav Brain Res; 1999 Feb; 99(1):27-34. PubMed ID: 10512569
[TBL] [Abstract][Full Text] [Related]
56. Cannabinoid receptors and reward in the rat: a conditioned place preference study.
Cheer JF; Kendall DA; Marsden CA
Psychopharmacology (Berl); 2000 Jul; 151(1):25-30. PubMed ID: 10958113
[TBL] [Abstract][Full Text] [Related]
57. Motivational effects of cannabinoids and opioids on food reinforcement depend on simultaneous activation of cannabinoid and opioid systems.
Solinas M; Goldberg SR
Neuropsychopharmacology; 2005 Nov; 30(11):2035-45. PubMed ID: 15812567
[TBL] [Abstract][Full Text] [Related]
58. Cannabidiol potentiates pharmacological effects of Delta(9)-tetrahydrocannabinol via CB(1) receptor-dependent mechanism.
Hayakawa K; Mishima K; Hazekawa M; Sano K; Irie K; Orito K; Egawa T; Kitamura Y; Uchida N; Nishimura R; Egashira N; Iwasaki K; Fujiwara M
Brain Res; 2008 Jan; 1188():157-64. PubMed ID: 18021759
[TBL] [Abstract][Full Text] [Related]
59. Prevention by the cannabinoid antagonist, SR141716A, of cannabinoid-mediated blockade of long-term potentiation in the rat hippocampal slice.
Collins DR; Pertwee RG; Davies SN
Br J Pharmacol; 1995 Jul; 115(6):869-70. PubMed ID: 7582512
[TBL] [Abstract][Full Text] [Related]
60. delta 9-Tetrahydrocannabinol increases activity of tyrosine hydroxylase in cultured fetal mesencephalic neurons.
Hernández ML; García-Gil L; Berrendero F; Ramos JA; Fernández-Ruiz JJ
J Mol Neurosci; 1997 Apr; 8(2):83-91. PubMed ID: 9188039
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
